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Background: Soil-transmitted helminthiasis affects almost 2 billion people worldwide in tropical climates. Preventive
chemotherapy, using the benzimidazoles (albendazole and mebendazole) is the current main recommended control
strategy. Nevertheless, there is limited efficacy of these drugs against hookworm infection and, to a greater extent,
against trichuriasis. We describe a protocol for a trial investigating the efficacy and safety of the co-administration of
ivermectin and albendazole against trichuriasis.
Methods: A double-blind, placebo-controlled randomized controlled trial will be conducted in three countries (Côte
d’Ivoire, Tanzania and Lao PDR) with the aim to determine the efficacy, safety and extended effects of co-administered
ivermectin and albendazole compared to standard albendazole monotherapy. We will enroll 600 participants
aged 6–60 years in each setting. The primary outcome is cure rate (CR) against Trichuris trichiura infection as
assessed by Kato-Katz 14–21 days after treatment. Secondary outcomes include CRs against concomitant soil-transmitted
helminth (STH) infections (Ascaris lumbricoides, hookworm and Strongyloides stercoralis) and egg reduction rates (ERRs)
against STH at 14–21 days, 180 days and 360 days. Tolerability of treatment, infection status assessed by polymerase chain
reaction (PCR), and potential benefits of deworming on nutritional and morbidity indicators will be assessed. The primary
analysis will include an available-case set and use logistic regression models adjusted for age, sex and weight.
Discussion: This trial will provide robust results on the efficacy and safety of co-administration of ivermectin and
albendazole with the aim to better inform WHO recommendations on control of STHs. Furthermore, secondary
and explanatory outcomes will provide direct evidence on the extended effects of combination therapy and insight on
the relationship between nutrition and morbidity parameters and infection status and intensity.
Trial registration: NCT03527732 (date assigned: 17 May 2018).
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Almost 2 billion people are infected with soil-transmitted
helminths (STHs), the majority being preschool and
school-aged children living in Asia and Africa [1, 2]. Ascaris
lumbricoides (roundworm), Trichuris trichiura (whipworm)
and Necator americanus or Ancylostoma duodenale (hook-
worms), the most common STHs, account for an annual
burden of 1.9 million disability-adjusted life-years (DALYs)
related to infection [1, 3]. Infection can be the result of the
ingestion of T. trichiura or A. lumbricoides eggs or the
penetration of skin by hookworm larvae [4]. Inadequate
access to clean water, poor hygiene and unimproved
sanitation lead to an increase in risk of STH infection,
thus particularly affecting populations in low- and
middle-income countries [4]. Morbidity due to STHs
are related mostly to high intensity infections and may
include acute symptoms such as diarrhea, dysentery,
abdominal pain or obstruction; if left untreated, STH
infections can lead to inflammation, nutrition and im-
mune system impairment and, finally, can cause phys-
ical and mental development retardation in children
and limited working capacity in adults [1, 4].
To date, preventive chemotherapy (PC) that is the
periodic administration of anthelminthic drugs to at-risk
populations without prior diagnosis, is the cornerstone
of helminth control put forth by the World Health
Organization (WHO) to reduce the burden of STHs. PC
is implemented in the form of annual mass drug adminis-
tration (MDA) campaigns and the recommended target
populations have been expanded from only school-aged
children to include younger children (1–5 years of age),
adolescent (10–19 years) girls, women of reproductive age
(15–49 years) and pregnant women after the first trimester
in areas with an STH prevalence of ≥20% [5]. A biannual
frequency of MDA is recommended in case of high preva-
lence (> 50%). Albendazole, one of the two main drugs
used for MDA, is considered safe and well tolerated; how-
ever, it is not efficient in clearing infection and redu-
cing worm loads in all three types of STHs [2, 6]. While
it shows satisfyingly high cure rates (CRs) (96%) and
egg reduction rates (ERRs) (> 98%) against A. lumbri-
coides, efficacy against hookworm is lower (CR = 80%
and ERR = 90%) and against Trichuris trichiura is dis-
turbingly low with CRs of 31% and ERRs of 50% [6].
Furthermore, this drug has been used for more than
three decades and comparison of efficacy measures
over time indicates a decreasing trend over time;
although resistance has so far not been documented in
its use in humans [5]. In view of insufficient efficacy,
especially against T. trichiura, coupled with the poten-
tial for resistance emergence from long-term use, there
is not only a pressing need for the development of new
treatments against STH infections, but also a need to
optimize current treatment schemes [7].The co-administration of standard drugs together with
other anthelminthics, such as ivermectin, could be a way
to achieve universal impact on all STH species [8].
Moreover, the combined use of ivermectin and albenda-
zole against STH infection has been added recently to
the WHO Model Lists of Essential Medicines paving the
way for application in control programs [9]. A recent
meta-analysis indeed shows a lower risk (risk ratio
(RR) =0.44) of still being positive for T. trichiura
post-treatment for co-administered ivermectin and alben-
dazole when compared to albendazole alone; however,
these findings are based on a very limited amount of quali-
fying studies (n = 3) conducted in various settings, limited
to school-aged children and/or adolescents with consider-
able variation among the reported efficacy measures [10].
Interestingly, two studies also highlight potential extended
effects on follow-up infection status or intensity (18 weeks
and 1 year) compared to single or other combined drug
regimens [11, 12]. To better inform and guide ongoing
helminth control programs on optimization and imple-
mentation of ivermectin-albendazole integrated treatment
schemes, a deeper understanding of its impact across a
range of different transmission settings, including a
broader age range and a prolonged monitoring period, is
needed.
To the best of our knowledge, this is the first large,
multi-country trial assessing the safety and efficacy of
the combination of ivermectin and albendazole and the
extended effects of treatment against T. trichiura.
Methods/design
Trial design
This is a multi-country, parallel group, double-blind,
placebo-controlled, randomized controlled trial (RCT). It
will be implemented as a community-based study target-
ing children, adolescents and adults aged 6 to 60 years. In
each of the three countries, 600T. trichiura-positive
community members will be randomly assigned to either
receive the current standard treatment (albendazole/pla-
cebo) or the combination therapy (ivermectin/albenda-
zole). All participating communities will be followed-up
over a period of one year including four assessment time
points at baseline, 3 weeks, 6 months and 12months after
treatment (see Fig. 1). The WHO Trial Registration Data
Set summarizes the most important trial information and
is given in Additional file 1. The study adheres to the
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) statement [13] and a checklist is
provided as supplementary file (see Additional file 2).
Study area and participants
The trial will be conducted in two African settings,
namely Côte d’Ivoire and Pemba Island, Tanzania, and
one Asian setting, Lao People’s Democratic Republic
Fig. 1 Design and timeline of the randomized controlled trial to be implemented in each of three settings. The study is designed as a two-armed
trial including one arm with a single drug administration (arm A; albendazole) and one arm with combined treatment through co-administration
of separate tablets (arm B; ivermectin and albendazole). The trial will be conducted as a multi-country study with two settings in Africa and one
in Asia, namely Côte d’Ivoire, Pemba (Zanzibar, Tanzania) and Lao PDR
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earlier findings and insights from local collaborators
on T. trichiura endemicity. In Côte d’Ivoire, the
Agnéby-Tiassa region in the southeast of the country
has been identified with high STH infection prevalence
(particularly for T. trichiura) in previous community-based
studies or RCTs [14, 15]. Pemba Island is still highly en-
demic to STH infections [16]. Potential study communities
on Pemba will be selected based on accessibility besides
T. trichiura endemicity. An area fulfilling these criteria is
considered the Shehia of Pujini, 9 km south-east of Chake
Chake, Pemba. In Lao PDR recent data suggests highest in-
fection rates for T. trichiura to be found in the northern
zone of the country including the province of Luang Pra-
bang [17]. In each study location community members
from 6 to 60 years of age will be invited for participation.
Recruitment
In order to recruit participants from a broad age range
(6–60 years), entire communities with less than 1000 in-
habitants (smaller communities are easier to be mobi-
lized and monitored) will be pre-screened and a census
conducted to identify T. trichiura cases and eligible indi-
viduals in each household, respectively.
All adult community members will be invited to par-
ticipate in an informational meeting explaining the pur-
poses and procedures of the study, including potentialbenefits and risks. In this open discussion forum, par-
ents/caregivers/potential participants will be encouraged
to ask questions and be informed of actions to prevent
acquiring STH infections in the future.
Individuals (including parents/caregivers of children)
interested in participating in the trial will be invited to
complete the process of informed consent; thereafter, in-
dividuals will be assessed for study eligibility during
screening procedures.
Eligibility criteria
Participants will be eligible to be included in the trial if
they fulfill all of the following criteria:
1. Provide written informed consent signed by either
the participant him/herself (≥18 years of age in Lao
PDR and Pemba, Tanzania or ≥ 21 years of age in
Côte d‘Ivoire) or by parents and/or caregivers for
children/adolescents; and oral assent by child/
adolescent (aged 6–17 years Lao PDR and Pemba,
Tanzania or aged 6–20 years in Côte d‘Ivoire).
2. Agree to comply with study procedures, including
provision of two stool samples at the beginning
(baseline) and on three follow-up assessments
(approximately 3 weeks, 6 months, and 12 months
later).
3. Aged ≥6 to ≤60 years and weighing at least 15 kg.
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of the quadruple Kato-Katz thick smears and infection
intensity of at least 100 eggs per gram (EPG) of stool.
Participants will be ineligible to be included in the trial
if they fulfill any of the following criteria:
1. Presence of major systemic illnesses, e.g. severe
anemia (below 80 g/l Hemoglobin (Hb) according to
WHO [18]), clinical malaria as assessed by a
medical doctor (positive Plasmodium rapid diagnostic
test (RDT) and ≥ 38 °C ear temperature), upon initial
clinical assessment.
2. History of acute or severe chronic disease (e.g.
cancer, diabetes, chronic heart, liver or renal disease).
3. Recent use of anthelmintic drug (within past 4 weeks).
4. Attendance in other clinical trials.
5. Known allergy to study medications (i.e. ivermectin
and albendazole).
6. Pregnancy or lactating in the 1st week after birth
(according to WHO guidelines within lymphatic
filariasis control programs [19]).
7. Current use of medication with known interaction
(e.g. for ivermectin: warfarin; for albendazole:
cimetidine, praziquantel and dexamethasone).
Intervention
All T. trichiura-infected, consenting, and participating
community members will be treated with the respective
single or combination treatment regimen at day 0. Re-treat-
ment with the intervention assigned at randomization will
occur at 6months in all participants found to be positive
for any STH. 400mg albendazole tablets will be the prod-
uct of Glaxo Smith Kline, UK (Zentel®) and a single tablet
will be administered. 3mg tablets of ivermectin (Stromec-
tol®) will be obtained from Merck, France and administered
at a dose of 200 μg/kg body weight recorded for each par-
ticipant. Matching ivermectin placebo tablets (in terms of
appearance) will be produced and a certificate of manufac-
ture and analysis be provided by the University of Basel.
Since ivermectin and albendazole are known to be better
absorbed in humans after a high-fat meal is consumed, par-
ticipants will receive a local high-fat breakfast prior to treat-
ment [20, 21]. After ingestion of the medication, the
subjects will be observed for 3 h to ensure retention of the
drug. Vomiting within 1-h post-dosing will require re-
dosing. The subjects will not be allowed more than one
repeated dose. No re-administration will be needed for sub-
jects vomiting after one hour.
Outcomes
Primary outcome
The primary outcome is T. trichiura infection status as
assessed by Kato-Katz 14–21 days after treatment measuredas CR, calculated as the percent of infected individuals at
baseline free from infection after treatment.
Secondary outcomes
Secondary outcomes include the ERR against T. trichiura,
CRs and ERRs against other concomitant STH infections
(A. lumbricoides, hookworm and Strongyloides stercoralis),
reinfection rates, tolerability of treatment and infection
status assessed by polymerase chain reaction (PCR).
Outcomes will be assessed at 14–21 days, 180 days and
360 days post-treatment.
Exploratory outcomes
Exploratory outcomes include the molecular characterization
of T. trichiura strains from different settings and investiga-
tion of potential resistance markers through deep sequencing
as well as the evaluation of the potential benefits of deworm-
ing on nutrition status and morbidity indicators.
Sample size calculation
Based on a recent systematic review and the published
literature, we assume that the CR of albendazole against
T. trichiura is 30% compared to 50% in the ivermectin-
albendazole treatment regimen [6]. To achieve a power of
90% at a significance level of 5%, 121 participants per study
arm are needed to detect a statistically significant difference.
With an estimated loss to follow-up of 15%, 143 participants
will be required in each study arm. Furthermore, we assume
the same treatment efficacy and a reinfection risk of 10% at
6months. Consequently we expect a proportion of negative
patients after 12months of 44% in the albendazole arm and
of 65% in the ivermectin-albendazole arm resulting in a re-
quired sample size of 111 participants per arm. To account
for a loss to follow-up of 30% after 6months and 40% at
final assessment (12months), we aim to recruit 300 partici-
pants in each treatment group (600 in total) in each country
for a total of 1800 participants.
Randomisation
Study participants eligible for treatment will be ran-
domly assigned in a 1:1 allocation to one of the treat-
ment arms using sealed, opaque sequentially-numbered
envelopes prepared by persons independent of the trial.
Since treatment success is influenced by infection inten-
sity, stratified block randomization will be used (baseline
infection intensity: light infections and moderate/heavy
infections) to ensure balanced treatment groups in terms
of infection intensity. The computer-generated stratified
randomization sequence, provided by a statistician, will
vary randomly in blocks of four, six and eight and will
be stratified by 2 levels of baseline infection intensity
(light: < 1000 EPG, and moderate and heavy: ≥1000 EPG
T. trichiura infections).
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The trial will be double-blinded (i.e. study participants
and the trial team/researchers conducting the treatment
and assessing the outcomes will be blinded). One 400
mg albendazole tablet will be given to each participant.
The ivermectin (or corresponding placebo) tablets used
for each treatment arm will be repacked into neutral
separate plastic bags each containing the maximum num-
ber of ivermectin tablets with regard to weight and dose or
the corresponding number of appearance-matched placebo
tablets produced by the University of Basel. If at any point
during the trial an unanticipated need to unblind a partici-
pant’s treatment allocation arises for reasons of safety, the
principal investigator, site investigators, and ethics commit-
tee will be notified and the instance will be documented.
Trial timeline
The trial will last for fourteen months. The screening for
the baseline will start three weeks prior to the treatment.
Follow-up screening will take place 14–21 days, 180 days
and 360 days post-treatment and each will last for about
three weeks. Schedules of visits are summarized in Table 1.
Data collection
All data besides a household questionnaire will be col-
lected during scheduled visits and recorded on paper
case report forms (CRFs), laboratory reporting forms or




Diagnosis (stool and urine examination) X







Plasmodium co-infection (in Côte d’Ivoire/ Lao PDR only)
W. bancrofti co-infection (in Africa only)






Treatment satisfactiondatabase using EpiInfo (v3.5.4). Access will be limited to
study investigators and study personnel entering data;
both working independently from the project funder.
Data reported in the household questionnaire will be
collected using paper forms in Pemba Island and using
Open Data Kit (ODK) on mobile tablet computer de-
vices in Côte d’Ivoire and Lao PDR where electronic
data collection has already been applied in earlier stud-
ies. Data entered via ODK collect will be uploaded to a
server hosted by the Swiss Tropical and Public Health
Institute (Swiss TPH; Basel, Switzerland). For quality as-
surance in-built error, range and consistency checks will
be programmed for the data entry masks (i.e., in EpiInfo
and ODK). The obtained data will be handled strictly
confidentially. Personal data will be coded for data ana-
lysis. No names will be published at any time, and pub-
lished reports will not allow for identification of single
subjects.
Clinical assessment
A clinical examination of the study participants assessing
general health (blood pressure, pulse rate, symptoms,
medical history, etc.), anthropometric parameters including
height, weight, mid-upper arm circumference (MUAC) and
skinfold thickness (i.e. tricep and subscapular skinfolds) as
well as tympanic temperature using an ear thermometer
(Braun Thermoscan 5, Braun GmbH, Kronberg, Germany)
will precede the treatment and will be repeated on twoBaseline/Treatment/Safety Follow-up
Hours Days
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tential benefits from deworming. Blood pressure will be
measured using a sphygmomanometer (OMRON M6,
Omron Healthcare CO., LTD, Kyoto, Japan). Body weight
will be measured using a mobile, digital scale (SECA Model
803, Seca Gmbh Co, Hamburg, Germany) with a precision
to the nearest 0.1 kg, while height will be measured using a
measuring stick in centimetres. Mid-upper arm circumfer-
ence will be measured to the nearest 0.1 cm using a MUAC
tape; and a caliper (Harpenden Skinfold Caliper, HaB Inter-
national Ltd., Warwickshire, England) will be used to meas-
ure tricep and subscapular skinfold thicknesses to the
nearest 0.2mm. All anthropometric measurements will be
taken twice, recorded and the average value then used. A
licensed physician will conduct a physical examination on
each participant before treatment at baseline, 6months and
12months.Biospecimen collection and testing
Stool samples
Community members providing informed consent will
be asked to provide two stool samples of at least 15 g
each within a maximum of 5 days at baseline. From every
stool specimen, duplicate Kato-Katz thick smears (41.7 mg
each) will be prepared and read under a microscope for
eggs of T. trichiura, A. lumbricoides and hookworm by ex-
perienced technicians [22]. A subsequent independent
quality control of sample results (approximately 10%) will
be conducted. All microscopically analyzed quadruplicate
Kato-Katz thick smears will be destroyed within one day
(after passing the quality control).
A portion of 2–3 g of stool from each specimen will be
preserved in 70% ethanol and shipped to the Swiss TPH,
Basel, Switzerland for PCR analysis which will allow fur-
ther classification of hookworm infection into the three
species N. americanus, A. duodenale and A. ceylanicum
[23]. A subsample of 10 participants with high intensity
infections following treatment from each of the settings
(30 in total) will be subjected to deep sequencing for
characterization of T. trichiura strains and investigation
of potential resistance markers [24].
Additionally, a small amount of feces (less than 1 mg)
from the second stool sample of participants identified
as positive for T. trichiura in the first sample will further
be tested for fecal occult blood and fecal calprotectin
(Actim Fecal Blood and Calprotectin, Oy Medix Biochemica
Ab, Espoo, Finland) as proxies for gut morbidity and
inflammation using a rapid diagnostic immunoassay
test [25]. In Lao PDR, the remains of each stool sample
(ideally 10 to 20 g) will be processed by the Baermann
technique for identification of S. stercoralis infections
and be recorded qualitatively as larva-positive or nega-
tive [26].Blood samples
Enrolled participants undergoing a clinical examination at
baseline, 6 months and 12months will be asked to provide
a finger-prick blood sample to evaluate Hb levels using a
HemoCue analyzer (Hemocue Hb 301 system; Angelholm,
Sweden). Additionally, participants in Côte d’Ivoire and
Lao PDR will be asked to provide a finger-prick blood
sample for an RDT (i.e. Humasis Pf/Pan and Humasis Pf/
Pv) for Plasmodium spp. infection, while participants in
Côte d’Ivoire and Pemba will be asked to provide a
finger-prick blood sample for an RDT (i.e. ENCODE Filar-
iasis IgG/IgM) detecting antibodies in the blood to iden-
tify potential co-infection with Wuchereria bancrofti, as
patients with filariasis have shown a significantly higher
frequency of adverse events after combined treatment
with ivermectin and albendazole [27, 28].
In one African (i.e., Côte d’Ivoire) and the Asian set-
ting (i.e., Lao PDR), participants will be asked to give
approximately 8 ml of venous blood at baseline, 6
months and 12 months to assess potential improve-
ment on nutritional indicators for micronutrient (i.e.
(pro-) vitamins, inflammation markers, and iron/fer-
ritin) and macronutrient (i.e. albumin) deficiencies.
Blood will be collected in EDTA and Serum Vacutai-
ners (BD, Franklin Lakes, NJ, USA). In Côte d’Ivoire
and Lao PDR we will undertake analysis of biochem-
ical and hematological parameters as a proxy for func-
tioning of vital organs. These parameters may include
urea, creatinine, bilirubin, azotemia, Alanine Amino
Transferase (ALAT), Aspartate Amino Transferase
(ASAT), hematocrit, erythrocytes and platelets. Serum
separated from collected blood in serum blood collec-
tion tubes after centrifugation will be aliquoted at
local laboratories in Côte d’Ivoire and Lao PDR and
then sent on dry ice to accredited reference laborator-
ies within Switzerland and Germany. Samples will be
kept at − 20 °C in field labs and in transport and stored at
− 80 °C in Switzerland and in Germany. Ferritin, soluble
transferrin receptor, retinol-binding protein, α1-acid
glycoprotein and C-reactive protein will be measured
using Sandwich enzyme-linked immunosorbent assay
(ELISA) techniques [29]. Transferrin will be measured
using immunoturbidimetry; iron will be measured using
spectrophotometry; hepcidin will be measured using a
solid phase ELISA; and vitamin A will be measured using
high performance liquid chromatography.Urine samples
Female participants over the age of ten years will be
asked to give a urine sample of at least 10 ml for a preg-
nancy RDT at baseline, 6 months and 12months before
(re-)treatment is administered to avoid accidental treat-
ment of pregnant girls/women.
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Household questionnaire
A household questionnaire will be administered to all
participating households between screening and 3 weeks
follow-up to assess socioeconomic factors (e.g. structure,
condition, amenities), presence of sanitation/water facil-
ities (e.g. shower, latrine/toilet, water sources), and hy-
giene attitudes/practices (e.g. defecation, hand-washing,
water use). Collected information will be used to assess
the relationship between reinfection rates and household
characteristics/behaviors; moreover, an evaluation of the
potential associations of high intensity and persistent in-
fections with sociodemographic characteristics will be
conducted.
Treatment satisfaction
Subjective treatment satisfaction will be assessed at 3 h,
3 weeks and 6months after treatment to investigate rela-
tionship with treatment compliance and observed effi-
cacy in reducing egg output and morbidity. Participants
will be asked to provide short-term treatment satisfac-
tion (e.g. convenience of treatment) at 3 h and 3 weeks
post-treatment, while long-term treatment satisfaction
(e.g. effectiveness in reducing symptoms) will be asked
at 6 months follow-up.
Physical functioning and well-being
Children 6 to 16 years of age will be administered a
patient-rated physical functioning and well-being ques-
tionnaire during clinical examination before treatment
and at 6 months and 12months follow-up using tools
already applied and evaluated in school-aged children
from rural settings in Côte d’Ivoire and pre-tested in a
comparable school-aged population not otherwise in-
volved in this trial [30].
Adverse events
Very few adverse events (AEs) are expected after
ivermectin-albendazole co-administration in STH-infected
individuals. The most common AEs reported were ab-
dominal cramps, headache, fatigue, nausea, diarrhea,
fever and vertigo [31–33].
Subjects will be kept for observation for at least 3 h
following treatment for any acute AEs. In addition, pa-
tients will also be interviewed 3 h, 24 h, and 3 weeks
after treatment about the occurrence of AEs. If there is
any abnormal finding, the local study physician will per-
form a full clinical, physical and biochemical examin-
ation and findings will be recorded. An emergency kit
will be available on site to treat any medical conditions
that warrant urgent medical intervention. Information
on all AEs (onset, duration, intensity, seriousness and
causality) will be immediately entered in the appropriate
AE module of the CRF that serves as source document.For all AEs and serious adverse events (SAEs), sufficient
information will be pursued and/or obtained so as to be
graded on severity, relatedness and expectedness. These
data will be recorded on the appropriate CRF sections, re-
gardless of whether they are thought to be associated with
the study or the drug under investigation. Any
study-related unanticipated problem posing risk of harm to
subjects or others (including all unexpected adverse
drug reactions) and any type of SAE will be immedi-
ately (within a maximum of 24 h after becoming aware
of the event) notified to the study sponsor-investigator
and co-PIs.
Statistical methods
The primary available-case analysis will include all par-
ticipants with primary endpoint data. In addition, an
intention-to-treat analysis for the primary endpoint
assessed at 3 weeks will be conducted considering all
participants with missing endpoint data as treatment
failure or all as treatment success to ensure that the re-
sults are not sensitive to potential loss to follow-up bias.
CRs will be calculated as the percentage of egg-positive
participants at baseline who become egg-negative after
treatment. Infection intensity expressed as the arithmetic
and geometric mean EPG will be calculated for each
treatment arm. EPG will be assessed by adding up the
egg counts from the quadruplicate Kato-Katz thick
smears and multiplying this number by a factor of six.












In the primary model we estimate the difference
among CRs by using unadjusted logistic regressions. In a
subsequent analysis an adjusted logistic regression (ad-
justment for age, sex and weight) will be performed.
Geometric mean egg counts will be calculated for the
different treatment arms before and after treatment to
assess the corresponding ERRs. Bootstrap resampling
method with 5000 replicates will be used to calculate
95% confidence intervals for ERRs and the difference be-
tween the ERRs.
Results from the stool RDT for fecal occult blood will
be categorized as negative, trace and positive. For cal-
protectin, the semiquantitative RDT allows classifying in-
dividuals by concentration into negative (levels below
50 μg/g of feces), low (50–200 μg/g) or high (≥ 200 μg/g)
intensities.
Anthropometric measurements such as height and
weight of school-aged children will be translated into
weight-for-age, height-for-age and weight-for-height re-
lated z-scores using readily available Stata commands
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5–19 years [34]. Body mass index and indicators for
muscle and fat tissue, such as MUAC and skinfold thick-
ness, will serve as additional indicators of nutritional sta-
tus for adults [35].
Questionnaires on physical functioning and treatment
satisfaction will be evaluated by creating summary scores
by summing up and transforming the single question
scores according to the following formula: [(actual raw
score-lowest possible raw score)/(possible raw score
range)]*100 [30].
Nutritional and morbidity indicators will be analyzed
using logistic and linear regression as appropriate. To
compare individual’s changes in nutrition/morbidity cat-
egories as an effect from treatment, McNemar’s test will
be applied. The analysis after 6 and 12months of
follow-up will be complemented by generalized estimating
equation models with independent correlation structure
and empirical estimators to account for missing data.
AEs will be evaluated descriptively as the difference of
proportion reporting AEs before and after treatment.
Discussion
Soil-transmitted helminthiasis remains a public health
burden in many low- and middle-income countries [4].
Since the passing of the resolution WHA 54.19 by the
World Health Assembly in 2001, great strides have been
taken to reduce the morbidity and mortality of STH infec-
tions [36]. With the changing epidemiological landscape
of soil-transmitted helminthiasis moving from control
to elimination, MDA implementation is shifting from
school-based to community-based [37, 38]. This trial
marks the first multi-country, longitudinal, randomized
double-blind controlled trial assessing the safety and ef-
ficacy of a combination therapy at the community level.
With the scaling up of PC programs, mounting drug
pressure increases the risk for drug resistance against the
benzimidazoles in populations infected by STHs. None-
theless, combination treatment of two or more drugs can
provide heightened efficacy and protection against drug
resistance [39]. Our data will provide robust evidence on
the possible increased efficacy and extended effects of
combined albendazole and ivermectin treatment when
compared to albendazole alone to pave the way of the
former as recommended treatment for soil-transmitted
helminthiasis for use in control programs.
We will report not only on efficacy and safety outcomes
of combination ivermectin and albendazole therapy, but
also the effects of drug administration on morbidity in a
broad age range. In the midst of controversy on the im-
pact of PC through mass deworming campaigns, this trial
provides direct evidence in determining the relationship
between deworming campaigns and clinical morbidity and
nutritional indicators [5, 40–44]. The role of vitamin A asa protective factor against re-infection will be assessed, as
well as the long-term (6 and 12months) effects of STH
therapy on anemia. Moreover, serum hepcidin levels will
be quantified to determine the dynamics between
iron-deficiency anemia, anemia of chronic disease and in-
fection status/intensity. The use of fecal rapid diagnostics
tests as surrogates for gut morbidity will provide a novel
proof of concept between STH infection status intensity.
These nutritional and gut parameters will be measured in
various settings (Asia and Africa) using standardized
methods at 6 and 12months in the hopes of providing
clarity to the potential impact of mass deworming in
communities.
We will also report on the differences in CRs and sensi-
tivity between the current diagnostic method recom-
mended by the WHO (Kato-Katz smear) and DNA-based
methods (qPCR). A major drawback of the Kato-Katz
method is the low sensitivity for infections of low intensity
[45]. As countries shift from STH control to elimination,
more sensitive methods of diagnosis are needed as infec-
tion intensities lower. PCR methods offer the advantage
that only single samples need to be taken and multiple in-
fections can be detected in one reading; however, esti-
mates of sensitivity vary and standardization of technique
is needed [46, 47]. This trial will provide an opportunity to
collect samples from various settings where co-infections
may vary and refine the current qPCR technique.
In conclusion, this trial will aim to generate evidence to
inform future WHO guidelines of STH therapy and its
impact on morbidity. Currently, the combination of iver-
mectin and albendazole is a safe and effective treatment
that is currently given to more than 500 million individ-
uals yearly as part of the Global Programme to Eliminate
Lymphatic Filariasis; and there may be opportunities to
transition the program to control and elimination of
soil-transmitted helminthiasis [48, 49]. However, evidence
on the efficacy of the co-administration of ivermectin and
albendazole against STHs from high quality RCTs is
needed to confirm results and scale up combination ther-
apy in endemic areas.
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